Projects In Knowledge Home

Latest Programs

Expert Insight Into: Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression

Dr. Rush
Faculty

Psychiatry Article Review - The use of atypical antipsychotic medications to treat both mania and depression has been proposed. This article review explores the therapeutic outcomes of using the atypical antipsychotic quetiapine in the treatment of bipolar depression. A. John Rush, MD, provides expert clinical insights on these findings. This course is part of The Advanced Certificate Program: Management of Mood Disorders. more »1

Expert Insights—Association Between Neocortical Volume Changes and Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis

Dr. Inglese
Faculty

Neurology Article Review - Could changes in neocortical gray matter volume be partly responsible for cognitive deterioration in patients with relapsing-remitting multiple sclerosis (RRMS)? This article review, which features clinical insights from Matilde Inglese, MD, PhD, reports on a recent study that related several different measures on quantitative MRI to cognitive decline in patients with early RRMS. This course is part of The Advanced Certificate Program: Multiple Sclerosis Management. more »2

Expert Insight Into: Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression

Dr. Rush
Faculty

Psychiatry Article Review - This article review, which features clinical insights by A. John Rush, MD, explores the therapeutic outcomes of switching to another selective serotonin reuptake inhibitor (SSRI) or to venlafaxine, as well as the use of adjunctive cognitive behavioral therapy, in the treatment of SSRI-resistant adolescent depression. This course is part of The Advanced Certificate Program: Management of Mood Disorders. more »3

Expert Insights—Update on Relapsing-Remitting MS:
B-cell Depletion with Rituximab

Dr. Cree
Faculty

Neurology Article Review - Recognition of the role of B lymphocytes in the pathophysiology of multiple sclerosis (MS) has stimulated interest in therapies that target these cells. This article review, featuring commentary by Bruce A. C. Cree, MD, PhD, MCR, discusses a recent clinical trial of the anti-CD20+ monoclonal antibody rituximab in patients with relapsing-remitting MS. This course is part of The Advanced Certificate Program: Multiple Sclerosis Management. more »4

Case Study: Oncology Care for Non–Small-Cell Lung Cancer Patients on Targeted Therapies

Dr. Gillespie and Ms. Knoop
Co-Chair and Faculty

Oncology Tx Reporter Newsletter - In this case study of a 45-year-old man receiving bevacizumab and erlotinib for treatment of advanced NSCLC, Teresa J. Knoop, MSN, RN, AOCN^®, reviews the latest research on the therapeutic indications and efficacy of targeted therapies in lung cancer treatment. Ms. Knoop differentiates the unique side effects of these agents and details strategies for managing patient adherence to maximize therapeutic improvements. This course is part of Caring for Oncology Patients: Tips and Tools for Managing Targeted Therapy. more »5

Case Study: MRI in Differential Diagnosis of MS

Dr. Miller and Dr. DeAngelis
Co-Chair and Faculty

Neurology Tx Reporter Newsletter - In this case-based Tx Reporter, Tracy M. DeAngelis, MD, navigates the complicated task of achieving an accurate diagnosis for a 31-year-old woman who presents with migraines and whose MRI suggests chronic demyelinating disease. Dr. DeAngelis illustrates the step-by-step process implemented to obtain a diagnosis, including the updated McDonald Criteria, the consideration of multiple conditions that could account for the MRI abnormalities, and the additional workup needed to rule out these conditions. This course is part of The Advanced Certificate Program: Multiple Sclerosis Management. more »6

Expert Insight Into: Molecular Mechanisms of Cardiotoxicity of Tyrosine Kinase Inhibition

Dr. Gillespie
Faculty

Oncology Article Review - A recent review discusses the cardiotoxicity associated with certain tyrosine kinase inhibitors and the possible mechanisms responsible for this effect. This review compares the signaling pathways of targeted therapy, the therapeutic response on cancer cells, and the effect on cardiac function. more »7

Lessons Learned from STEP-BD Study

Dr. Evans and Dr. Thase
Moderator and Presenter

Psychiatry Audio Interview - Michael E. Thase, MD, explains the STEP-BD study’s findings and their implications for clinical practice. Remission (defined as ≤2 symptoms for at least 8 weeks) was the primary endpoint of the study. STEP-BD uncovered new information about treatment protocols for people with major depressive disorder, and people who are treatment resistant, as well as the importance of psychotherapy in achieving and maintaining remission. Characteristics of people who are more likely to remit or relapse are discussed. Thase also relates how measurement-based tools can help physicians objectively gauge patients’ symptoms. This audio interview represents Course 11 of The Advanced Certificate Program: Management of Mood Disorders. more »8

Expert Insight Into: Mood Switch in Bipolar Depression: Comparison of Adjunctive Venlafaxine, Bupropion, and Sertraline

Dr. Thase
Faculty

Psychiatry Article Review - In a recent clinical trial, three antidepressants with differing mechanisms of action were compared for their effects on rates of response, remission, and switching to mania in patients with bipolar disorder. Michael E. Thase, MD, provides expert clinical insights on the study findings in this article review, which represents a course of The Advanced Certificate Program: Management of Mood Disorders. more »9

Expert Insights—Mechanisms for Altering the Natural History of MS

Dr. Cross
Faculty

Neurology Article Review - A primary goal of treating relapsing-remitting MS is to delay the progression of disability. The use of interferon-β to treat MS has been widely accepted, but its long-term effectiveness in delaying disability remains unknown. In this article review, Anne H. Cross, MD, provides expert clinical insights on the findings of a recent observational study that assessed the long-term effectiveness of interferon-β on disability outcomes. This course is part of The Advanced Certificate Program: Multiple Sclerosis Management. more »10


Browse Home » Cardiology » Gastroenterology » Infectious Diseases » Managed Care » Neurology » Oncology » Ophthalmology » Psychiatry » Latest News powered by:	Latest Programs Expert Insight Into: Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression Dr. Rush Faculty Psychiatry Article Review - The use of atypical antipsychotic medications to treat both mania and depression has been proposed. This article review explores the therapeutic outcomes of using the atypical antipsychotic quetiapine in the treatment of bipolar depression. A. John Rush, MD, provides expert clinical insights on these findings. This course is part of The Advanced Certificate Program: Management of Mood Disorders. more »1 Expert Insights—Association Between Neocortical Volume Changes and Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis Dr. Inglese Faculty Neurology Article Review - Could changes in neocortical gray matter volume be partly responsible for cognitive deterioration in patients with relapsing-remitting multiple sclerosis (RRMS)? This article review, which features clinical insights from Matilde Inglese, MD, PhD, reports on a recent study that related several different measures on quantitative MRI to cognitive decline in patients with early RRMS. This course is part of The Advanced Certificate Program: Multiple Sclerosis Management. more »2 Expert Insight Into: Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression Dr. Rush Faculty Psychiatry Article Review - This article review, which features clinical insights by A. John Rush, MD, explores the therapeutic outcomes of switching to another selective serotonin reuptake inhibitor (SSRI) or to venlafaxine, as well as the use of adjunctive cognitive behavioral therapy, in the treatment of SSRI-resistant adolescent depression. This course is part of The Advanced Certificate Program: Management of Mood Disorders. more »3 Expert Insights—Update on Relapsing-Remitting MS: B-cell Depletion with Rituximab Dr. Cree Faculty Neurology Article Review - Recognition of the role of B lymphocytes in the pathophysiology of multiple sclerosis (MS) has stimulated interest in therapies that target these cells. This article review, featuring commentary by Bruce A. C. Cree, MD, PhD, MCR, discusses a recent clinical trial of the anti-CD20+ monoclonal antibody rituximab in patients with relapsing-remitting MS. This course is part of The Advanced Certificate Program: Multiple Sclerosis Management. more »4 Case Study: Oncology Care for Non–Small-Cell Lung Cancer Patients on Targeted Therapies Dr. Gillespie and Ms. Knoop Co-Chair and Faculty Oncology Tx Reporter Newsletter - In this case study of a 45-year-old man receiving bevacizumab and erlotinib for treatment of advanced NSCLC, Teresa J. Knoop, MSN, RN, AOCN^®, reviews the latest research on the therapeutic indications and efficacy of targeted therapies in lung cancer treatment. Ms. Knoop differentiates the unique side effects of these agents and details strategies for managing patient adherence to maximize therapeutic improvements. This course is part of Caring for Oncology Patients: Tips and Tools for Managing Targeted Therapy. more »5 Case Study: MRI in Differential Diagnosis of MS Dr. Miller and Dr. DeAngelis Co-Chair and Faculty Neurology Tx Reporter Newsletter - In this case-based Tx Reporter, Tracy M. DeAngelis, MD, navigates the complicated task of achieving an accurate diagnosis for a 31-year-old woman who presents with migraines and whose MRI suggests chronic demyelinating disease. Dr. DeAngelis illustrates the step-by-step process implemented to obtain a diagnosis, including the updated McDonald Criteria, the consideration of multiple conditions that could account for the MRI abnormalities, and the additional workup needed to rule out these conditions. This course is part of The Advanced Certificate Program: Multiple Sclerosis Management. more »6 Expert Insight Into: Molecular Mechanisms of Cardiotoxicity of Tyrosine Kinase Inhibition Dr. Gillespie Faculty Oncology Article Review - A recent review discusses the cardiotoxicity associated with certain tyrosine kinase inhibitors and the possible mechanisms responsible for this effect. This review compares the signaling pathways of targeted therapy, the therapeutic response on cancer cells, and the effect on cardiac function. more »7 Lessons Learned from STEP-BD Study Dr. Evans and Dr. Thase Moderator and Presenter Psychiatry Audio Interview - Michael E. Thase, MD, explains the STEP-BD study’s findings and their implications for clinical practice. Remission (defined as ≤2 symptoms for at least 8 weeks) was the primary endpoint of the study. STEP-BD uncovered new information about treatment protocols for people with major depressive disorder, and people who are treatment resistant, as well as the importance of psychotherapy in achieving and maintaining remission. Characteristics of people who are more likely to remit or relapse are discussed. Thase also relates how measurement-based tools can help physicians objectively gauge patients’ symptoms. This audio interview represents Course 11 of The Advanced Certificate Program: Management of Mood Disorders. more »8 Expert Insight Into: Mood Switch in Bipolar Depression: Comparison of Adjunctive Venlafaxine, Bupropion, and Sertraline Dr. Thase Faculty Psychiatry Article Review - In a recent clinical trial, three antidepressants with differing mechanisms of action were compared for their effects on rates of response, remission, and switching to mania in patients with bipolar disorder. Michael E. Thase, MD, provides expert clinical insights on the study findings in this article review, which represents a course of The Advanced Certificate Program: Management of Mood Disorders. more »9 Expert Insights—Mechanisms for Altering the Natural History of MS Dr. Cross Faculty Neurology Article Review - A primary goal of treating relapsing-remitting MS is to delay the progression of disability. The use of interferon-β to treat MS has been widely accepted, but its long-term effectiveness in delaying disability remains unknown. In this article review, Anne H. Cross, MD, provides expert clinical insights on the findings of a recent observational study that assessed the long-term effectiveness of interferon-β on disability outcomes. This course is part of The Advanced Certificate Program: Multiple Sclerosis Management. more »10	Featured Programs Living Medical Textbook Oncology Tumor Immunology and Immunotherapy: Metastatic Melanoma Edition Mini- Symposia Unraveling the Complexities of Menopause Management Webcast Available Now Webcast Available Now Targeting the Microtubule in Breast Cancer New Course of The Advanced Certificate Program: Breast Cancer Management A Sea Change in MS Treatment— The Potential of Small Molecules On-Demand Interactive Webcast Available Now The Advanced Certificate Program: Multiple Sclerosis Management Available Now The Advanced Certificate Program: Breast Cancer Management Certificate Program The Art of Individualized Treatment in the Management of Colorectal Cancer On-Demand Webcast Available Now Translating Clinical Trial Data into the Community Setting: A Case-Based Approach to Metastatic Colorectal Cancer On-Demand Webcast Available Now An Interactive, Case-Based Approach to Targeted Therapies for GIST On-Demand Webcast Available Now The Advanced Certificate Program: Management of Mood Disorders Register Today Caring for Oncology Patients: Tips and Tools for Managing Targeted Therapy An Ongoing Online CME/CE Curriculum Available Now The Advanced Certificate Program: Lung Cancer Management II *Coming Soon* The Advanced Certificate Program: Lung Cancer Management Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities Certificate Program Hepatitis C: From Scientific Foundations to New Vistas in Treatment Webcast Now Available